Supergenics Stock

SGBHD

MYL03033O007

Biotechnology & Medical Research

Delayed BURSA MALAYSIA 03:50:01 2025-12-30 EST			5-day change	1st Jan Change
0.2500 ^MYR	+21.95%		-.--%	-

08-28	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-29	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI

Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
SGBHD Stock

As early as today, start finding the best investment opportunities!

Market Cap	29.11M 7.13M 6.29M 5.95M 5.4M 10.12M 684M 10.22M 71.41M 27.52M 349M 26.77M 26.19M 1.12B	P/E 2024	-9.45x	P/E 2025	-8.61x
Enterprise Value	32.5M 7.96M 7.03M 6.65M 6.03M 11.3M 764M 11.41M 79.74M 30.73M 390M 29.89M 29.24M 1.26B	EV / Sales 2024	13.9x	EV / Sales 2025	5.78x
Free-Float	41.6%	Yield 2024 *	-	Yield 2025	-

08-28	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-29	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
02-27	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-05	Supergenics Seeks 6-Month Extension to Complete Private Placement of Shares	MT
25-08-29	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-27	Supergenics fixes issue price at 0.27 RGT per share	RE
25-08-12	Supergenics Berhad Announces the Redesignation of Lau Meng Hong from Executive Director to Non Independent and Non Executive Director, Effective August 12, 2025	CI
25-03-21	Supergenics Berhad Announces Change of Registered Office Address	CI
25-02-28	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-08-30	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-04-01	Supergenics Seeks More Time to Complete Private Share Placement	MT
24-02-29	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-29	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI

1 year	0.2	0.25
3 years	0.15	0.6
5 years	0.15	0.6
10 years	0.15	0.6

Manager	Title	Age	Since
Bii Chau Tan CEO	Chief Executive Officer	48	2019-04-23
Yuet Chyn Wong SEC	Corporate Secretary	-	2022-06-01

Director	Title	Age	Since
Bii Chau Tan BRD	Director/Board Member	48	2019-04-23
Fun Kim Ng BRD	Director/Board Member	60	2019-04-23
Kiat Yang Chan BRD	Director/Board Member	46	2022-01-27

Supergenics Stock

Stocks

SGBHD

MYL03033O007

Biotechnology & Medical Research

Valuation: Supergenics

Chart: Supergenics

Latest news: Supergenics

Quotes and Performance

Price Extremes

Managers and Directors: Supergenics

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUPERGENICS	+21.95%	-.--%	-16.67%	+8.70%	7.13M
LONZA GROUP AG	-0.03%	+3.77%	+12.35%	+37.22%	49.06B
IQVIA HOLDINGS INC.	-0.73%	-0.41%	+48.84%	+36.72%	44.6B
REVOLUTION MEDICINES, INC.	+1.36%	+6.03%	+343.85%	+638.73%	43.24B
BEONE MEDICINES AG	-0.47%	-0.76%	+9.75%	+103.07%	41.73B
CELLTRION, INC.	+0.34%	+0.22%	+5.18%	+47.36%	29.93B
MEDPACE HOLDINGS, INC.	+1.00%	-1.28%	+24.23%	+156.93%	17.19B
TEMPUS AI, INC.	-2.94%	+6.98%	+5.10%	-	15.35B
EUROFINS SCIENTIFIC SE	-3.20%	-3.50%	+25.33%	+42.43%	15.54B
ASCENDIS PHARMA A/S	-0.86%	-4.00%	-	-	15.11B
Average	+1.64%	+1.02%	+50.88%	+133.89%	27.18B
Weighted average by Cap.	-0.28%	+1.79%	+74.43%	+166.43%

	2024	2025
Net sales	5.32M 1.3M 1.15M 1.09M 987K 1.85M 125M 1.87M 13.06M 5.03M 63.87M 4.89M 4.79M 206M	5.63M 1.38M 1.22M 1.15M 1.04M 1.96M 132M 1.98M 13.8M 5.32M 67.51M 5.17M 5.06M 217M
Net income	-7.28M -1.78M -1.57M -1.49M -1.35M -2.53M -171M -2.56M -17.86M -6.88M -87.38M -6.7M -6.55M -281M	-3.37M -824K -727K -688K -624K -1.17M -79.1M -1.18M -8.26M -3.18M -40.39M -3.1M -3.03M -130M
Net Debt	4.48M 1.1M 968K 916K 830K 1.56M 105M 1.57M 10.98M 4.23M 53.73M 4.12M 4.03M 173M	3.39M 831K 734K 694K 629K 1.18M 79.77M 1.19M 8.33M 3.21M 40.73M 3.12M 3.05M 131M